220 related articles for article (PubMed ID: 22879788)
1. Treatment of type 1 and type 2 diabetes mellitus with insulin detemir, a long-acting insulin analog.
Young JR; McAdam-Marx C
Clin Med Insights Endocrinol Diabetes; 2010; 3():65-80. PubMed ID: 22879788
[TBL] [Abstract][Full Text] [Related]
2. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
[TBL] [Abstract][Full Text] [Related]
3. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
[TBL] [Abstract][Full Text] [Related]
4. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
Hemmingsen B; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis.
Tunis SL; Minshall ME; Conner C; McCormick JI; Kapor J; Yale JF; Groleau D
Curr Med Res Opin; 2009 May; 25(5):1273-84. PubMed ID: 19366302
[TBL] [Abstract][Full Text] [Related]
6. Insulins NPH, glargine, and detemir, and risk of severe hypoglycemia among working-age adults.
Strandberg AY; Khanfir H; Mäkimattila S; Saukkonen T; Strandberg TE; Hoti F
Ann Med; 2017 Jun; 49(4):357-364. PubMed ID: 28042719
[TBL] [Abstract][Full Text] [Related]
7. The Comparative Dosing and Glycemic Control of Intermediate and Long-Acting Insulins in Adult Patients With Type 1 and 2 Diabetes Mellitus.
Kabakov A; Merker A
J Pharm Technol; 2022 Feb; 38(1):46-53. PubMed ID: 35141727
[TBL] [Abstract][Full Text] [Related]
8. Is insulin detemir able to favor a lower variability in the action of injected insulin in diabetic subjects?
Valensi P; Cosson E
Diabetes Metab; 2005 Sep; 31(4 Pt 2):4S34-4S39. PubMed ID: 16389896
[TBL] [Abstract][Full Text] [Related]
9. Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia.
Johansen OE; Vanberg PJ; Kilhovd BK; Jørgensen AP
Vasc Health Risk Manag; 2009; 5(1):121-8. PubMed ID: 19436668
[TBL] [Abstract][Full Text] [Related]
10. Insulin detemir: a review of its use in the management of diabetes mellitus.
Keating GM
Drugs; 2012 Dec; 72(17):2255-87. PubMed ID: 23110609
[TBL] [Abstract][Full Text] [Related]
11. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
Hollander P; Cooper J; Bregnhøj J; Pedersen CB
Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
[TBL] [Abstract][Full Text] [Related]
12. An update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog.
Raslova K
Vasc Health Risk Manag; 2010 Jun; 6():399-410. PubMed ID: 20539842
[TBL] [Abstract][Full Text] [Related]
13. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir.
Peterson GE
Curr Med Res Opin; 2006 Dec; 22(12):2613-9. PubMed ID: 17166343
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the incidence and risk of hypoglycemic coma associated with selection of basal insulin in the treatment of diabetes: a Finnish register linkage study.
Haukka J; Hoti F; Erästö P; Saukkonen T; Mäkimattila S; Korhonen P
Pharmacoepidemiol Drug Saf; 2013 Dec; 22(12):1326-35. PubMed ID: 24150837
[TBL] [Abstract][Full Text] [Related]
15. Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis.
Tricco AC; Ashoor HM; Antony J; Beyene J; Veroniki AA; Isaranuwatchai W; Harrington A; Wilson C; Tsouros S; Soobiah C; Yu CH; Hutton B; Hoch JS; Hemmelgarn BR; Moher D; Majumdar SR; Straus SE
BMJ; 2014 Oct; 349():g5459. PubMed ID: 25274009
[TBL] [Abstract][Full Text] [Related]
16. A cost comparison of long-acting insulin analogs vs NPH insulin-based treatment in patients with type 2 diabetes using routinely collected primary care data from the UK.
Idris I; Gordon J; Tilling C; Vora J
J Med Econ; 2015 Apr; 18(4):273-82. PubMed ID: 25422990
[TBL] [Abstract][Full Text] [Related]
17. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart.
Vague P; Selam JL; Skeie S; De Leeuw I; Elte JW; Haahr H; Kristensen A; Draeger E
Diabetes Care; 2003 Mar; 26(3):590-6. PubMed ID: 12610006
[TBL] [Abstract][Full Text] [Related]
18. Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia.
Davies MJ; Derezinski T; Pedersen CB; Clauson P
Diabetes Technol Ther; 2008 Aug; 10(4):273-7. PubMed ID: 18715200
[TBL] [Abstract][Full Text] [Related]
19. Spotlight on insulin detemir in type 1 and 2 diabetes mellitus.
Chapman TM; Perry CM
BioDrugs; 2005; 19(1):67-9. PubMed ID: 15691219
[TBL] [Abstract][Full Text] [Related]
20. Defining the role of insulin detemir in Basal insulin therapy.
Morales J
Drugs; 2007; 67(17):2557-84. PubMed ID: 18034591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]